Chemokine News and Research

RSS
Chemokines are a family of small cytokines, or proteins secreted by cells. Proteins are classified as chemokines according to shared structural characteristics such as small size (they are all approximately 8-10 kilodaltons in size), and the presence of four cysteine residues in conserved locations that are key to forming their 3-dimensional shape.
ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

ChemoCentryx announces the initiation of Phase I clinical trial of CCX168

Elevated cytokine levels are early indicator of rheumatoid arthritis

Elevated cytokine levels are early indicator of rheumatoid arthritis

Babraham Institute research may lead to new means of making purified T cells

Babraham Institute research may lead to new means of making purified T cells

GSK exercises option to obtain exclusive license to develop and commercialize Traficet-EN

GSK exercises option to obtain exclusive license to develop and commercialize Traficet-EN

Inovio Biomedical expands existing license agreement with the University of Pennsylvania

Inovio Biomedical expands existing license agreement with the University of Pennsylvania

Funxional Therapeutics completes Phase I study of FX125L

Funxional Therapeutics completes Phase I study of FX125L

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

UAB professors honored for scientific contributions and outstanding mentorship

UAB professors honored for scientific contributions and outstanding mentorship

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

Cardiologists receive K23 research grant from NIH

Cardiologists receive K23 research grant from NIH

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Updated clinical data of Calistoga Pharmaceuticals’ delta selective PI3K inhibitor presented

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

Additional data from ChemoCentryx' study of Traficet-EN in Crohn's disease patients

Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology

Preclinical and Phase I data for TG-0054 presented by TaiGen Biotechnology

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

Positive Phase II/III clinical data from ChemoCentryx' PROTECT-1 Traficet-EN trial

CXCL5 molecule causes insulin resistance and type 2 diabetes in obese people

CXCL5 molecule causes insulin resistance and type 2 diabetes in obese people

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

Ohr Pharmaceutical to develop OHR/AVR118 for cachexia treatment

NOXXON Pharma commences human dosing in Spiegelmer NOX-A12 clinical trial

NOXXON Pharma commences human dosing in Spiegelmer NOX-A12 clinical trial

Helper T cell's effect raises possibility of cellular therapy and vaccine development

Helper T cell's effect raises possibility of cellular therapy and vaccine development

NOXXON Pharma announces the successful completion of the first phase I trial of Spiegelmer NOX-E36

NOXXON Pharma announces the successful completion of the first phase I trial of Spiegelmer NOX-E36

Aushon BioSystems completes construction of new laboratory and manufacturing facility

Aushon BioSystems completes construction of new laboratory and manufacturing facility

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.